受强制性开放获取政策约束的文章 - Katherine McNamara (Pogrebniak)了解详情
可在其他位置公开访问的文章：9 篇
Clonal replacement of tumor-specific T cells following PD-1 blockade
KE Yost, AT Satpathy, DK Wells, Y Qi, C Wang, R Kageyama, ...
Nature medicine 25 (8), 1251-1259, 2019
强制性开放获取政策： US National Science Foundation, US National Institutes of Health, Howard …
Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer
M Murtaza, SJ Dawson, K Pogrebniak, OM Rueda, E Provenzano, J Grant, ...
Nature communications 6 (1), 8760, 2015
强制性开放获取政策： Cancer Research UK, UK Medical Research Council, National Institute for …
A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds
A Bruna, OM Rueda, W Greenwood, AS Batra, M Callari, RN Batra, ...
Cell 167 (1), 260-274. e22, 2016
强制性开放获取政策： US National Institutes of Health, Cancer Research UK, UK Medical Research …
Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response
KL McNamara, JL Caswell-Jin, R Joshi, Z Ma, E Kotler, GR Bean, ...
Nature cancer 2 (4), 400-413, 2021
强制性开放获取政策： US National Institutes of Health, Damon Runyon Cancer Research Foundation …
Novel insights into breast cancer copy number genetic heterogeneity revealed by single-cell genome sequencing
T Baslan, J Kendall, K Volyanskyy, K McNamara, H Cox, S D'Italia, ...
elife 9, e51480, 2020
强制性开放获取政策： US Department of Defense, US National Institutes of Health, Susan G. Komen
Harnessing tumor evolution to circumvent resistance
KL Pogrebniak, C Curtis
Trends in Genetics 34 (8), 639-651, 2018
强制性开放获取政策： US National Institutes of Health, Susan G. Komen
Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy
JL Caswell-Jin, K McNamara, JG Reiter, R Sun, Z Hu, Z Ma, J Ding, ...
Nature communications 10 (1), 657, 2019
强制性开放获取政策： US Department of Defense, US National Institutes of Health, Austrian Science …
Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)
SA Hurvitz, JL Caswell-Jin, KL McNamara, JJ Zoeller, GR Bean, ...
Nature communications 11 (1), 5824, 2020
强制性开放获取政策： US Department of Defense, US National Institutes of Health, Damon Runyon …
Transcriptome and genome evolution during HER2-amplified breast neoplasia
P Lu, J Foley, C Zhu, K McNamara, K Sirinukunwattana, S Vennam, ...
Breast Cancer Research 23, 1-15, 2021
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定